DiscGenics Raises $50 Million in Series C Funding

SALT LAKE CITY, Aug. 25, 2020 -- (Healthcare Sales & Marketing Network) -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative dis... Regenerative Medicine, Orthopaedic, Venture Capital DiscGenics, Discogenic Cells
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news